HopeStage
Back to all studies
CompletedNCT04818086

Lemborexant with buprenorphine and naloxone: safety and drug interactions

About this title

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Read the official source — NCT04818086
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
RichmondSee all locations and recruitment
Participation duration
About 4 weeks
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 3, 2021
Recruitment status
Completed
Enrollment listed in the registry
18
Sponsor
Virginia Commonwealth University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04818086
Official title
Show the full official title

Phase Ib/2a Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Richmond

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Virginia Commonwealth University, a university.

Did this study involve medication?

Yes. The study involved medication, including Lemborexant, Placebo and Buprenorphine-naloxone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies